Skip to content
DataLookout
Menu

Huawei-SunU01NCT07913581

Real-World Validation of A Huawei Smartwatch for Hypertension Risk Screening in Malaysia

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Diagnostic Accuracy (AUC-ROC) of the Huawei PPG Smartwatch Hypertension Risk Algorithm Compared to 24-Hour Ambulatory Blood Pressure Monitoring (ABPM)
Timeframe: Month 11 through Month 18.
Diagnostic Sensitivity of the Huawei PPG Smartwatch Hypertension Risk Algorithm
Timeframe: Month 11 through Month 18.
Diagnostic Specificity of the Huawei PPG Smartwatch Hypertension Risk Algorithm
Timeframe: Month 11 through Month 18.
Positive Predictive Value (PPV) of the Huawei PPG Smartwatch Hypertension Risk Algorithm
Timeframe: Month 11 through Month 18
Negative Predictive Value (NPV) of the Huawei PPG Smartwatch Hypertension Risk Algorithm
Timeframe: Month 11 through Month 18

Secondary (2)

Participant Adherence to Huawei Wearable Monitoring Protocols
Participant Usability and Acceptance Score Measured via Post-Monitoring Questionnaire

Arms and interventions

Screening Population

Adults enrolled in the community screening phase who undergo non-invasive blood pressure estimation using the Huawei PPG smartwatch over the 24-month study period.

High-Risk Validation Cohort

A targeted subset of participants (n = 50) identified as high-risk for hypertension by the Huawei smartwatch screening tool, who undergo 24-hour Ambulatory Blood Pressure Monitoring (ABPM) to confirm their diagnostic status.

Sites

1 site in 1 country

  • Faculty of Medical and Life Sciences, Sunway UniversitySubang Jaya, Selangor, Malaysia